Acute Lymphocytic Leukemia Case Study Noah

Methods

Cohorts

An adult AML cohort was generated from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registry.11,12 Only AML cases at ≥18 years of age registered between 2000 and 2010 were examined. APL cases were excluded (ICD-0-3 code 9866/3). We narrowed our search to Hispanics and non-Hispanic whites. We extracted data on demographics, year of diagnosis, duration of follow-up, and vital status.

Cytogenetic information available in the SEER registry was primarily informative for the t(8;21)(q22;q22)RUNX1-RUNX1T1, inv(16)(p13.1q22), and t(16;16)(p13.1;q22)CBFB-MYH11 alterations and did not allow complete cytogenetic risk classification. Two prognostic groups were developed: a favorable group (for the core binding factor leukemias) and a nonfavorable group (for all other cases).

A validation cohort was generated from a minority-rich population of AML patients treated within the Montefiore Medical system in the Bronx, NY, from 1 January 2000 to 31 December 2010, with the use of Clinical Looking Glass, a software tool developed at Montefiore Medical Center. It included all Hispanic and white newly diagnosed AML patients aged ≥18 years. Demographic information was obtained at patient registration. Ethnicity and race were self-reported.

Manual chart review retrieved data on date of diagnosis, cytogenetics, prior chemotherapy/radiation or myeloid neoplasm, treatment (including allogeneic transplantation), response, and date of death or last known encounter. Three cytogenetic risk categories were generated.13⇓⇓-16 All cases of APL were excluded.

We performed targeted sequencing at 500× coverage (Genoptix, Carlsbad, CA) for genomic profiling of AML cases in Bronx, NY, from 30 November 2013 to 30 October 2016. In conjunction with data from The Cancer Genome Atlas (TCGA) Network,17 we looked for genomic differences by ethnicity. The study was approved by the Montefiore-Einstein institutional review board in accordance with the Declaration of Helsinki.

Statistical analysis

Age distribution between Hispanic and white AML patients was compared with the Mann-Whitney U test. Comparison of proportions was done with the Pearson’s χ2 test or Fisher’s exact test for scarce data.

Differences in survival between Hispanics and whites were assessed with the Kaplan-Meier function and tested with the log-rank test. Multivariable Cox proportional hazard models were constructed to look at the mortality risk associated with ethnicity, adjusted for age, sex, cytogenetic risk (in both cohorts) and initial therapy (in the Bronx cohort). Variables selected on the basis of their clinical significance were forced to the models. The linearity assumption was evaluated with fractional polynomial regression, postestimation partial residual plots, and the dummy variable method. The proportional hazard assumption was tested by analysis of Schoenfeld residuals and assessed graphically with log–log curves. Statistical significance was determined at the 2-tailed α .05 level.

Statistical analyses were performed with STATA software, version 12.0.

Results and discussion

The SEER cohort consisted of 2664 Hispanic and 20 905 white AML patients (Table 1). The median follow-up time was 8 months. Hispanics were diagnosed at a significantly younger age than whites (median age 59 vs 71 years; P < .001) and had a slightly higher representation of favorable risk cytogenetics (3.9 vs 2.6%; P < .001) (Table 1). Multivariable Cox regression analysis adjusted for age, sex, and cytogenetics showed significantly shorter overall survival (OS) in Hispanics compared with whites (hazard ratio, 1.08; 95% confidence interval, 1.02-1.13; P < .01); the median survival 26 months for Hispanics <50 years and 33 months for whites within the same age range.

The Bronx validation cohort included 152 patients (73 Hispanic and 79 non-Hispanic white) (Table 1), with a median follow-up time of 6.8 months. Similar to SEER, Hispanics were younger than whites at diagnosis (median age, 59 vs 71 years; P < .001) but had similar cytogenetic risk distribution (P = .28). There were no significant differences in rates of intensive chemotherapy (65.8 vs 49.4%; P = .08) (Table 1) or complete remission (68.4 vs 75.8%; P = .49) between Hispanics and whites. The rates of allogeneic transplantation were similar (Hispanics: 9.6%; whites: 8.9%; P = .98). The age-adjusted OS was significantly shorter for Hispanics than for whites (hazard ratio, 1.79, 95% confidence interval, 1.10-2.90; P = .02) in a multivariable Cox model that additionally adjusted for sex, cytogenetic risk, and selected therapy.

Mutational analysis in a Bronx subcohort revealed no statistically significant differences in the frequency of ASXL1 (19.6 vs 12.0%; P = .52) and TET2 mutations (23.9 vs 20.0%; P = .71) in Hispanics and whites, possibly due to small numbers. However, analysis of a combined cohort with additional AML cases genotyped by the TCGA demonstrated significantly higher frequency of ASXL1 (P < .001) and TET2 mutations (P = .03) in Hispanics than in whites (Table 2).

Differences in treatment intensity are difficult to ascertain outside a randomized clinical trial. In the validation cohort, we found similar rates of intensive chemotherapy, per standard of care protocols, and allogeneic transplantation in both Hispanics and whites. Superior clinical fitness in the younger Hispanic group, donor availability in multimember Hispanic families, and use of haploidentical donors could have counterbalanced minority underrepresentation in donor registries. We had no information on socioeconomic status (SES); however, in the urban population represented by our single-institution cohort, no substantial variations in SES are expected. The concordant results in both cohorts further argue against the confounding effect of treatment or SES. Although a cohort and not a population-based study to allow age-specific AML incidence estimation, the size of the SEER-generated cohort study provides large-scale evidence of differences in age of AML presentation and outcomes between Hispanics and whites. These observations were confirmed in our ethnically diverse validation cohort.

In contrast to Swords et al and in concordance with Patel et al, we observed that Hispanics present with AML at a younger age compared with whites.8,10 In addition, age-adjusted OS was surprisingly worse in Hispanics, a result particularly intriguing when seen in context with the so-called Hispanic epidemiologic paradox.18 Finally, in our study, we attempted for the first time to compare the genomic profile of myeloid neoplasms between the 2 ethnic groups. Differences in representation of Hispanics and de novo cases in the TCGA and Bronx cohorts could confound the comparison and future studies are required for further verification. However, the combined cohort provided a sizeable pool of genomic data, and the results suggest the presence of mutations of adverse prognostic significance at higher frequency in Hispanic than white AML patients, which may provide a biologic explanation for the inferior outcomes of the former.

The underlying cause of the observed ethnic differences in age of onset and biologic behavior of AML remains elusive. Future investigation into how the complex interaction between environmental exposures and genetic factors impacts AML development may one day help to further elucidate our observations. These data support ethnicity-specific analysis of germline and somatic mutations in future studies.

Table 1.

Patient and disease characteristics by ethnicity in the SEER and validation cohorts

Table 2.

Frequency of common mutations in Bronx AML cohort and a combined Bronx and TCGA AML cohort

Authorship

Contribution: K.D., A.S., A.B., A.V., and I.M. conceived the idea and designed this study; K.D., A.S., A.B., D.H., R.S., K.P., J.S.-E., S.G., M.J., A.F.B., N.S.K., O.D., K.G., U.S., I.B., A.V., and I.M. carried out the study; I.M. and K.P. analyzed the data; and K.D., A.S., and A.B. wrote the initial draft of the paper, which was revised and approved by all authors.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Ioannis Mantzaris, Albert Einstein College of Medicine/Montefiore Medical Center, 111 East 210th St, Hofheimer 100, Bronx, NY 10467; e-mail: i.mantzar{at}montefiore.org.

Footnotes

  • ↵* K.D., A.S., and A.B. are joint first authors.

  • Submitted March 21, 2017.
  • Accepted September 4, 2017.
  • © 2017 by The American Society of Hematology

References

  1. 1.↵
  2. 2.↵
  3. 3.↵
  4. 4.↵
  5. 5.↵
  6. 6.↵
  7. 7.↵
  8. 8.↵
  9. 9.↵
  10. 10.↵
  11. 11.↵
  12. 12.↵
  13. 13.↵
  14. 14.↵
  15. 15.↵
  16. 16.↵
  17. 17.↵
  18. 18.↵

In September 2016, we shared the heartwarming story of young Noah Woods of Marion, and his inspiring journey as he courageously battles acute lymphoblastic leukemia (ALL).

A year later, we check in with Noah and his family. Noah’s mother, Michele Woods, catches us up on his progress. Read her update below.


Noah continues with his chemotherapy treatments: taking oral chemo each day at home and traveling back to the Mission Children’s Hospital suite at the SECU Cancer Center for his chemo infusion every 28 days along with the IT chemo every 3 months.

We have been very blessed Noah has been able to go to school and play baseball.

In fact, to look at him you would think he is a normal healthy child. He has been able to be a “normal” 6-year-old, except for his chemotherapy each night.

He still loves to play jokes on the staff and chase them with rubber spiders. The interdisciplinary team at the SECU Cancer Center has helped Noah tremendously throughout his treatment. They are wonderful.

We are very grateful to all of the staff at Mission Children’s Hospital, including the Child Life Specialist who has helped Noah understand his diagnosis and relieve any anxiety he’s had.

Noah will continue his treatment until March 2019. We know he will have both good days and bad.

We also know the providers and staff at Mission Children’s Hospital are excellent and are always just a phone call away.

It is amazing to think about what these kids with cancer must go through, yet they get up every day with a smile and are ready to fight. They are truly superheroes.


To learn more about the pediatric cancer services at Mission Children’s Hospital, visit missionchildrens.org.


New!

 Subscribe to health and wellness topics to be delivered to your inbox each week.

0 Thoughts to “Acute Lymphocytic Leukemia Case Study Noah

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *